P2 purinergic receptor dysregulation in urologic disease.
Extracellular ATP
P2X
P2Y
Prostate cancer
Purinergic receptors
Urologic disease
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
18
03
2022
accepted:
25
05
2022
pubmed:
11
6
2022
medline:
24
8
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
P2 purinergic receptors are involved in the normal function of the kidney, bladder, and prostate via signaling that occurs in response to extracellular nucleotides. Dysregulation of these receptors is common in pathological states and often associated with disease initiation, progression, or aggressiveness. Indeed, P2 purinergic receptor expression is altered across multiple urologic disorders including chronic kidney disease, polycystic kidney disease, interstitial cystitis, urinary incontinence, overactive bladder syndrome, prostatitis, and benign prostatic hyperplasia. P2 purinergic receptors are likewise indirectly associated with these disorders via receptor-mediated inflammation and pain, a common characteristic across most urologic disorders. Furthermore, select P2 purinergic receptors are overexpressed in urologic cancer including renal cell carcinoma, urothelial carcinoma, and prostate adenocarcinoma, and pre-clinical studies depict P2 purinergic receptors as potential therapeutic targets. Herein, we highlight the compelling evidence for the exploration of P2 purinergic receptors as biomarkers and therapeutic targets in urologic cancers and other urologic disease. Likewise, there is currently optimism for P2 purinergic receptor-targeted therapeutics for the treatment of inflammation and pain associated with urologic diseases. Further exploration of the common pathways linking P2 purinergic receptor dysregulation to urologic disease might ultimately help in gaining new mechanistic insight into disease processes and therapeutic targeting.
Identifiants
pubmed: 35687210
doi: 10.1007/s11302-022-09875-1
pii: 10.1007/s11302-022-09875-1
pmc: PMC9184359
doi:
Substances chimiques
Receptors, Purinergic P2
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-287Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Burnstock G (2012) Purinergic signalling: its unpopular beginning, its acceptance and its exciting future. BioEssays 34:218–225. https://doi.org/10.1002/bies.201100130
doi: 10.1002/bies.201100130
pubmed: 22237698
Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509
pubmed: 4404211
Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. Nature 509:310–317. https://doi.org/10.1038/nature13085
doi: 10.1038/nature13085
pubmed: 24828189
pmcid: 4222675
Samways DSK, Li Z, Egan TM (2014) Principles and properties of ion flow in P2X receptors. Front Cell Neurosci 8:6–6. https://doi.org/10.3389/fncel.2014.00006
doi: 10.3389/fncel.2014.00006
pubmed: 24550775
pmcid: 3914235
Ford AP (2012) In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 8:3–26. https://doi.org/10.1007/s11302-011-9271-6
doi: 10.1007/s11302-011-9271-6
pubmed: 22095157
Donnelly-Roberts D, McGaraughty S, Shieh C-C, Honore P, Jarvis MF (2008) Painful purinergic receptors. J Pharmacol Exp Ther 324:409–415. https://doi.org/10.1124/jpet.106.105890
doi: 10.1124/jpet.106.105890
pubmed: 18042830
von Kügelgen I, Wetter A (2000) Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol 362:310–323. https://doi.org/10.1007/s002100000310
doi: 10.1007/s002100000310
Somers GR, Hammet FM, Trute L, Southey MC, Venter DJ (1998) Expression of the PY purinergic receptor in human T cells infiltrating inflammatory bowel disease. Lab Investig; J Tech Methods Pathol 78:1375–1383
Coutinho-Silva R, Parsons M, Robson T, Lincoln J, Burnstock G (2003) P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats. Mol Cell Endocrinol 204:141–154. https://doi.org/10.1016/S0303-7207(03)00003-0
doi: 10.1016/S0303-7207(03)00003-0
pubmed: 12850289
Moore D, Iritani S, Chambers J, Emson P (2000) Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer’s disease. NeuroReport 11:3799–3803. https://doi.org/10.1097/00001756-200011270-00041
doi: 10.1097/00001756-200011270-00041
pubmed: 11117494
Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA (2004) Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44:206–215. https://doi.org/10.1111/j.0309-0167.2004.01798.x
doi: 10.1111/j.0309-0167.2004.01798.x
pubmed: 14987223
Mihai S, Codrici E, Popescu ID, Enciu A-M, Albulescu L, Necula LG, Mambet C, Anton G, Tanase C (2018) Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res 2018:2180373. https://doi.org/10.1155/2018/2180373
Marcu I, Campian EC, Tu FF (2018) Interstitial cystitis/bladder pain syndrome. Sem Reprod Med 36:123–135. https://doi.org/10.1055/s-0038-1676089
doi: 10.1055/s-0038-1676089
Contreras-Sanz A, Krska L, Balachandran AA, Curtiss NL, Khasriya R, Kelley S, Strutt M, Gill HS, Taylor KM, Mansfield KJ, Wu C, Peppiatt-Wildman CM, Malone-Lee J, Duckett J, Wildman SS (2016) Altered urothelial ATP signaling in a major subset of human overactive bladder patients with pyuria. Am J Physiol Renal Physiol 311:F805–F816. https://doi.org/10.1152/ajprenal.00339.2015
doi: 10.1152/ajprenal.00339.2015
pubmed: 27358056
Krieger JN, Nyberg J, Leroy and Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282 236–237 10–1001/pubs.JAMA-ISSN-0098–7484–282–3-jac90006
Egan KB (2016) The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 43:289–297. https://doi.org/10.1016/j.ucl.2016.04.001
doi: 10.1016/j.ucl.2016.04.001
pubmed: 27476122
Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15:11–24. https://doi.org/10.1038/nrurol.2017.167
doi: 10.1038/nrurol.2017.167
pubmed: 29089606
de Vivar Chevez AR, Finke J, Bukowski R (2014) The role of inflammation in kidney cancer. Adv Exp Med Biol 816:197–234. https://doi.org/10.1007/978-3-0348-0837-8_9
doi: 10.1007/978-3-0348-0837-8_9
pubmed: 24818725
Gakis G (2014) The role of inflammation in bladder cancer. Adv Exp Med Biol 816:183–196. https://doi.org/10.1007/978-3-0348-0837-8_8
doi: 10.1007/978-3-0348-0837-8_8
pubmed: 24818724
Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045. https://doi.org/10.1146/annurev.iy.12.040194.005015
doi: 10.1146/annurev.iy.12.040194.005015
pubmed: 8011301
Di Virgilio F (2007) Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci 28:465–472. https://doi.org/10.1016/j.tips.2007.07.002
doi: 10.1016/j.tips.2007.07.002
pubmed: 17692395
Falzoni S, Donvito G, Virgilio FD (2013) Detecting adenosine triphosphate in the pericellular space. Interface Focus 3:20120101. https://doi.org/10.1098/rsfs.2012.0101
doi: 10.1098/rsfs.2012.0101
pubmed: 23853707
pmcid: 3638417
Burnstock G (2016) P2X ion channel receptors and inflammation. Purinergic Signalling 12:59–67. https://doi.org/10.1007/s11302-015-9493-0
doi: 10.1007/s11302-015-9493-0
pubmed: 26739702
pmcid: 4749528
Antonioli L, Blandizzi C, Pacher P, Haskó G (2019) The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol Rev 71:345–382. https://doi.org/10.1124/pr.117.014878
doi: 10.1124/pr.117.014878
pubmed: 31235653
pmcid: 6592405
Aielli F, Ponzetti M, Rucci N (2019) Bone metastasis pain, from the bench to the bedside. Int J Mol Sci 20(2):280. https://doi.org/10.3390/ijms20020280
doi: 10.3390/ijms20020280
pmcid: 6359191
Chen C-C, Akopian AN, Sivilottit L, Colquhoun D, Burnstock G, Wood JN (1995) A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377:428–431. https://doi.org/10.1038/377428a0
doi: 10.1038/377428a0
pubmed: 7566119
Kaan TK, Yip PK, Patel S, Davies M, Marchand F, Cockayne DA, Nunn PA, Dickenson AH, Ford AP, Zhong Y, Malcangio M, McMahon SB (2010) Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain: J Neurol 133:2549–2564. https://doi.org/10.1093/brain/awq194
Vonend O, Oberhauser V, Von Kügelgen I, Apel TW, Amann K, Ritz E, Rump LC (2002) ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 61:1617–1626. https://doi.org/10.1046/j.1523-1755.2002.00315.x
doi: 10.1046/j.1523-1755.2002.00315.x
pubmed: 11967011
Menzies RI, Booth JWR, Mullins JJ, Bailey MA, Tam FWK, Norman JT, Unwin RJ (2017) Hyperglycemia-induced renal P2X7 receptor activation enhances diabetes-related injury. EBioMedicine 19:73–83. https://doi.org/10.1016/j.ebiom.2017.04.011
doi: 10.1016/j.ebiom.2017.04.011
pubmed: 28434946
pmcid: 5440600
Craigie E, Menzies RI, Larsen CK, Jacquillet G, Carrel M, Wildman SS, Loffing J, Leipziger J, Shirley DG, Bailey MA, Unwin RJ (2018) The renal and blood pressure response to low sodium diet in P2X4 receptor knockout mice. Physiol Rep 6:e13899. https://doi.org/10.14814/phy2.13899
Vallon V, Stockand J, Rieg T (2012) P2Y receptors and kidney function. Wiley Interdiscip Rev Memb Trans Signal 1:731–742. https://doi.org/10.1002/wmts.61
doi: 10.1002/wmts.61
Rieg T, Bundey RA, Chen Y, Deschenes G, Junger W, Insel PA, Vallon V (2007) Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption. Faseb J 21:3717–3726. https://doi.org/10.1096/fj.07-8807com
Rieg T, Gerasimova M, Boyer JL, Insel PA, Vallon V (2011) P2Y2 receptor activation decreases blood pressure and increases renal Na+ excretion. Am J Physiol Regul Integr Comp Physiol 301:R510–R518. https://doi.org/10.1152/ajpregu.00148.2011
doi: 10.1152/ajpregu.00148.2011
pubmed: 21613580
pmcid: 3154711
Stokes L, Scurrah K, Ellis Justine A, Cromer Brett A, Skarratt Kristen K, Gu Ben J, Harrap Stephen B, Wiley James S (2011) A loss-of-function polymorphism in the human P2X4 receptor is associated with increased pulse pressure. Hypertension 58:1086–1092. https://doi.org/10.1161/HYPERTENSIONAHA.111.176180
Center for Disease Control and Prevention. Chronic kidney disease surveillance system - United States. http://www.cdc.gov/ckd
Chen TK, Knicely DH, Grams ME (2019) Chronic kidney disease diagnosis and management: a review. JAMA 322:1294–1304. https://doi.org/10.1001/jama.2019.14745
doi: 10.1001/jama.2019.14745
pubmed: 31573641
pmcid: 7015670
Granata S, Masola V, Zoratti E, Scupoli MT, Baruzzi A, Messa M, Sallustio F, Gesualdo L, Lupo A, Zaza G (2015) NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. PLoS ONE 10:e0122272. https://doi.org/10.1371/journal.pone.0122272
Solini A, Menini S, Rossi C, Ricci C, Santini E, Blasetti Fantauzzi C, Iacobini C, Pugliese G (2013) The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol 231:342–353. https://doi.org/10.1002/path.4237
doi: 10.1002/path.4237
pubmed: 23843215
Lajdova I, Oksa A, Horvathova M, Spustova V (2017) Expression of purinergic P2X7 receptors in subpopulations of peripheral blood mononuclear cells in early-stage of chronic kidney disease. J Physiol Pharmacol : Off J Polish Physiol Soc 68:779–785
Lajdova I, Oksa A, Chorvat D Jr, Topor P, Spustova V (2012) Purinergic P2X7 receptors participate in disturbed intracellular calcium homeostasis in peripheral blood mononuclear cells of patients with chronic kidney disease. Kidney Blood Press Res 35:48–57. https://doi.org/10.1159/000330349
doi: 10.1159/000330349
pubmed: 21860249
Potthoff SA, Stegbauer J, Becker J, Wagenhaeuser PJ, Duvnjak B, Rump LC, Vonend O (2013) P2Y2 receptor deficiency aggravates chronic kidney disease progression. Front Physiol 4:234. https://doi.org/10.3389/fphys.2013.00234
doi: 10.3389/fphys.2013.00234
pubmed: 24065922
pmcid: 3776930
Rabadi M, Kim M, Li H, Han SJ, Choi Y, D’Agati V, Lee HT (2018) ATP induces PAD4 in renal proximal tubule cells via P2X7 receptor activation to exacerbate ischemic AKI. Am J Physiol Renal Physiol 314:F293–F305. https://doi.org/10.1152/ajprenal.00364.2017
doi: 10.1152/ajprenal.00364.2017
pubmed: 29021225
Hsu RK, Hsu C-Y (2016) The role of acute kidney injury in chronic kidney disease. Semin Nephrol 36:283–292. https://doi.org/10.1016/j.semnephrol.2016.05.005
doi: 10.1016/j.semnephrol.2016.05.005
pubmed: 27475659
pmcid: 4979984
Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008) The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74:101–107. https://doi.org/10.1038/ki.2008.107
doi: 10.1038/ki.2008.107
pubmed: 18385668
pmcid: 2673528
Bellomo R, Kellum JA, Ronco C (2012) Acute kidney injury. Lancet 380:756–766. https://doi.org/10.1016/S0140-6736(11)61454-2
doi: 10.1016/S0140-6736(11)61454-2
pubmed: 22617274
Han SJ, Lovaszi M, Kim M, D’Agati V, Haskó G, Lee HT (2020) P2X4 receptor exacerbates ischemic AKI and induces renal proximal tubular NLRP3 inflammasome signaling. Faseb J 34:5465–5482. https://doi.org/10.1096/fj.201903287R
doi: 10.1096/fj.201903287R
pubmed: 32086866
Yan Y, Bai J, Zhou X, Tang J, Jiang C, Tolbert E, Bayliss G, Gong R, Zhao TC, Zhuang S (2015) P2X7 receptor inhibition protects against ischemic acute kidney injury in mice. Am J Physiol Cell Physiol 308:C463-472. https://doi.org/10.1152/ajpcell.00245.2014
doi: 10.1152/ajpcell.00245.2014
pubmed: 25588875
pmcid: 4360025
Battistone MA, Mendelsohn AC, Spallanzani RG, Allegretti AS, Liberman RN, Sesma J, Kalim S, Wall SM, Bonventre JV, Lazarowski ER, Brown D, Breton S(2020) Pro-inflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice. J Clin Investig. https://doi.org/10.1172/JCI134791
Polycystic kidney disease. U.S. National Library of Medicine (2020).
Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Primers 4:50–50. https://doi.org/10.1038/s41572-018-0047-y
doi: 10.1038/s41572-018-0047-y
pubmed: 30523303
pmcid: 6592047
Turner CM, Ramesh B, Srai SK, Burnstock G, Unwin RJ (2004) Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease. Cells Tissues Organs 178:168–179. https://doi.org/10.1159/000082247
doi: 10.1159/000082247
pubmed: 15655334
Chang MY, Lu JK, Tian YC, Chen YC, Hung CC, Huang YH, Chen YH, Wu MS, Yang CW, Cheng YC (2011) Inhibition of the P2X7 receptor reduces cystogenesis in PKD. J Am Soc Nephrol 22:1696–1706. https://doi.org/10.1681/asn.2010070728
doi: 10.1681/asn.2010070728
pubmed: 21636640
pmcid: 3171940
Hillman KA, Woolf AS, Johnson TM, Wade A, Unwin RJ, Winyard PJ (2004) The P2X7 ATP receptor modulates renal cyst development in vitro. Biochem Biophys Res Commun 322:434–439. https://doi.org/10.1016/j.bbrc.2004.07.148
doi: 10.1016/j.bbrc.2004.07.148
pubmed: 15325248
Schwiebert EM, Wallace DP, Braunstein GM, King SR, Peti-Peterdi J, Hanaoka K, Guggino WB, Guay-Woodford LM, Bell PD, Sullivan LP, Grantham JJ, Taylor AL (2002) Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys. Am J Physiol-Renal Physiol 282:F763–F775. https://doi.org/10.1152/ajprenal.0337.2000
doi: 10.1152/ajprenal.0337.2000
pubmed: 11880338
Wilson PD, Hovater JS, Casey CC, Fortenberry JA, Schwiebert EM (1999) ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys. J Am Soc Nephrol 10:218–229
doi: 10.1681/ASN.V102218
Palygin O, Ilatovskaya DV, Levchenko V, Klemens CA, Dissanayake L, Williams AM, Pavlov TS, Staruschenko A (2018) Characterization of purinergic receptor expression in ARPKD cystic epithelia. Purinergic Signal 14:485–497. https://doi.org/10.1007/s11302-018-9632-5
doi: 10.1007/s11302-018-9632-5
pubmed: 30417216
pmcid: 6298916
Linehan WM, Ricketts CJ (2019) The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol 16:539–552. https://doi.org/10.1038/s41585-019-0211-5
doi: 10.1038/s41585-019-0211-5
pubmed: 31278395
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April 2017
Maynard JP, Lee J-S, Sohn BH, Yu X, Lopez-Terrada D, Finegold MJ, Goss JA, Thevananther S (2015) P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget 6:41162–41179
doi: 10.18632/oncotarget.6240
Nylund G, Hultman L, Nordgren S, Delbro DS (2007) P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton Autacoid Pharmacol 27:79–84. https://doi.org/10.1111/j.1474-8673.2007.00389.x
doi: 10.1111/j.1474-8673.2007.00389.x
pubmed: 17391276
Künzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, Halaceli I, Büchler MW, Friess H, Robson SC (2007) Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol - Gastrointest Liver Physiol 292:G223–G230
doi: 10.1152/ajpgi.00259.2006
Liu Z, Liu Y, Xu L, An H, Chang Y, Yang Y, Zhang W, Xu J (2015) P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci 106:1224–1231. https://doi.org/10.1111/cas.12736
doi: 10.1111/cas.12736
pubmed: 26179886
pmcid: 4582993
Gong D, Zhang J, Chen Y, Xu Y, Ma J, Hu G, Huang Y, Zheng J, Zhai W, Xue W (2019) The m(6)A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca(2+) influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway. J Exp Clin Cancer Res: CR 38:233. https://doi.org/10.1186/s13046-019-1223-y
doi: 10.1186/s13046-019-1223-y
pubmed: 31159832
pmcid: 6547495
Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G (2009) High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 9:152. https://doi.org/10.1186/1471-2407-9-152
doi: 10.1186/1471-2407-9-152
pubmed: 19445733
pmcid: 2686725
Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse D, Perlman EJ (2005) Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 11:7986–7994. https://doi.org/10.1158/1078-0432.ccr-05-1354
doi: 10.1158/1078-0432.ccr-05-1354
pubmed: 16299227
Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13:4740–4749. https://doi.org/10.1158/1078-0432.ccr-07-0143
doi: 10.1158/1078-0432.ccr-07-0143
pubmed: 17699851
Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG Jr, Signoretti S (2009) Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69:4674–4681. https://doi.org/10.1158/0008-5472.can-09-0146
doi: 10.1158/0008-5472.can-09-0146
pubmed: 19470766
pmcid: 2745239
Díez-Villanueva A, Mallona I, Peinado MA (2015) Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin 8:22. https://doi.org/10.1186/s13072-015-0014-8
doi: 10.1186/s13072-015-0014-8
pubmed: 26113876
pmcid: 4480445
Ruggieri MR Sr (2006) Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction. Nat Clin Pract Urol 3:206–215. https://doi.org/10.1038/ncpuro0456
doi: 10.1038/ncpuro0456
pubmed: 16607369
Takezawa K, Kondo M, Nonomura N, Shimada S (2017) Urothelial ATP signaling: what is its role in bladder sensation? Neurourol Urodyn 36:966–972. https://doi.org/10.1002/nau.23099
doi: 10.1002/nau.23099
pubmed: 27542121
Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, Roppolo JR, Ford AP, de Groat WC, Burnstock G (2004) Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am J Physiol Renal Physiol 287:F1084–F1091. https://doi.org/10.1152/ajprenal.00118.2004
doi: 10.1152/ajprenal.00118.2004
pubmed: 15251862
Silva I, Ferreirinha F, Magalhães-Cardoso MT, Silva-Ramos M, Correia-de-Sá P (2015) Activation of P2Y6 receptors facilitates nonneuronal adenosine triphosphate and acetylcholine release from urothelium with the lamina propria of men with bladder outlet obstruction. J Urol 194:1146–1154. https://doi.org/10.1016/j.juro.2015.05.080
doi: 10.1016/j.juro.2015.05.080
pubmed: 26004864
Tempest HV, Dixon AK, Turner WH, Elneil S, Sellers LA, Ferguson DR (2004) P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU Int 93:1344–1348. https://doi.org/10.1111/j.1464-410X.2004.04858.x
doi: 10.1111/j.1464-410X.2004.04858.x
pubmed: 15180635
Liu H-T, Kuo H-C (2017) Expressions of urothelial functional proteins in idiopathic detrusor overactivity patients refractory to antimuscarinic therapy with different urodynamic characteristics. Neurourol Urodyn 36:1313–1319. https://doi.org/10.1002/nau.23138
doi: 10.1002/nau.23138
pubmed: 27654640
Shabir S, Cross W, Kirkwood LA, Pearson JF, Appleby PA, Walker D, Eardley I, Southgate J (2013) Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium. Am J Physiol Renal Physiol 305:F396-406. https://doi.org/10.1152/ajprenal.00127.2013
doi: 10.1152/ajprenal.00127.2013
pubmed: 23720349
pmcid: 3742863
Kira S, Yoshiyama M, Tsuchiya S, Shigetomi E, Miyamoto T, Nakagomi H, Shibata K, Mochizuki T, Takeda M, Koizumi S (2017) P2Y6-deficiency increases micturition frequency and attenuates sustained contractility of the urinary bladder in mice. Sci Rep 7:771. https://doi.org/10.1038/s41598-017-00824-2
doi: 10.1038/s41598-017-00824-2
pubmed: 28396595
pmcid: 5429706
Liu M, Xu Y-F, Feng Y, Yang F-Q, Luo J, Zhai W, Che J-P, Wang G-C, Zheng J-H (2013) Epigallocatechin gallate attenuates interstitial cystitis in human bladder urothelium cells by modulating purinergic receptors. J Surg Res 183:397–404. https://doi.org/10.1016/j.jss.2012.11.041
doi: 10.1016/j.jss.2012.11.041
pubmed: 23260235
Vacca F, D’Ambrosi N, Nestola V, Amadio S, Giustizieri M, Cucchiaroni ML, Tozzi A, Velluz MC, Mercuri NB, Volonte C (2011) N-Glycans mutations rule oligomeric assembly and functional expression of P2X3 receptor for extracellular ATP. Glycobiology 21:634–643. https://doi.org/10.1093/glycob/cwq211
doi: 10.1093/glycob/cwq211
pubmed: 21186285
Irwin GM (2019) Urinary incontinence. Prim Care: Clin Off Practice 46:233–242. https://doi.org/10.1016/j.pop.2019.02.004
doi: 10.1016/j.pop.2019.02.004
Carneiro I, Timoteo MA, Silva I, Vieira C, Baldaia C, Ferreirinha F, Silva-Ramos M, Correia-de-Sa P (2014) Activation of P2Y6 receptors increases the voiding frequency in anaesthetized rats by releasing ATP from the bladder urothelium. Br J Pharmacol 171:3404–3419. https://doi.org/10.1111/bph.12711
doi: 10.1111/bph.12711
pubmed: 24697602
pmcid: 4105929
Moore KH, Ray FR, Barden JA (2001) Loss of purinergic P2X3 and P2X5 receptor innervation in human detrusor from adults with urge incontinence. J Neurosci 21:RC166–RC166. https://doi.org/10.1523/JNEUROSCI.21-18-j0002.2001
doi: 10.1523/JNEUROSCI.21-18-j0002.2001
pubmed: 11549755
pmcid: 6763010
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21:5–26. https://doi.org/10.1007/s00192-009-0976-9
doi: 10.1007/s00192-009-0976-9
pubmed: 19937315
Firouzmand S, Ajori L, Towse J, Allameh F, Najafi S, Javed S, John B, Langley SEM, Fry CH, Young JS (2020) Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder. Neurourol Urodyn 39:926–934. https://doi.org/10.1002/nau.24322
doi: 10.1002/nau.24322
pubmed: 32049380
pmcid: 8164356
Hao Y, Wang L, Chen H, Hill WG, Robson SC, Zeidel ML, Yu W (2019) Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. JCI Insight 4(16):e122112. https://doi.org/10.1172/jci.insight.122112
Sterle I, Zupancic D, Romih R (2014) Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder. Biomed Res Int 2014:805236. https://doi.org/10.1155/2014/805236
doi: 10.1155/2014/805236
pubmed: 24868547
pmcid: 4020497
Ding M, Zhan H, Liao X, Li A, Zhong Y, Gao Q, Liu Y, Huang W, Cai Z (2018) Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer. Int J Biol Sci 14:1268–1276. https://doi.org/10.7150/ijbs.27151
doi: 10.7150/ijbs.27151
pubmed: 30123075
pmcid: 6097482
Puppo V, Puppo G (2016) Comprehensive review of the anatomy and physiology of male ejaculation: premature ejaculation is not a disease. Clin Anat 29:111–119. https://doi.org/10.1002/ca.22655
doi: 10.1002/ca.22655
pubmed: 26457680
Haynes JM, Ventura S (2005) Current models of human prostate contractility. Clin Exp Pharmacol Physiol 32:797–804. https://doi.org/10.1111/j.1440-1681.2005.04268.x
doi: 10.1111/j.1440-1681.2005.04268.x
pubmed: 16173939
White CW, Short JL, Evans RJ, Ventura S (2015) Development of a P2X1-purinoceptor mediated contractile response in the aged mouse prostate gland through slowing down of ATP breakdown. Neurourol Urodyn 34:292–298. https://doi.org/10.1002/nau.22519
doi: 10.1002/nau.22519
pubmed: 24249481
Rodríguez D, Olumi AF (2012) Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol 4:325–334. https://doi.org/10.1177/1756287212447839
doi: 10.1177/1756287212447839
pubmed: 23205059
pmcid: 3491755
Ramamurthy R, Periasamy S, Mettupalayam V (2011) Primary malignancy of seminal vesicle: a rare entity. Indian J Urol 27:137–139. https://doi.org/10.4103/0970-1591.78417
doi: 10.4103/0970-1591.78417
pubmed: 21716878
pmcid: 3114576
Yeung C-H, Wang K, Cooper TG (2012) Why are epididymal tumours so rare? Asian J Androl 14:465–475. https://doi.org/10.1038/aja.2012.20
doi: 10.1038/aja.2012.20
pubmed: 22522502
pmcid: 3720153
Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA (2006) Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 175:1937–1942. https://doi.org/10.1016/s0022-5347(05)00892-x
doi: 10.1016/s0022-5347(05)00892-x
pubmed: 16600802
Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS (2018) Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol 199:161–171. https://doi.org/10.1016/j.juro.2017.08.001
doi: 10.1016/j.juro.2017.08.001
pubmed: 28797714
Slater M, Barden JA, Murphy CR (2000) The purinergic calcium channels P2X1,2,5,7 are down-regulated while P2X3,4,6 are up-regulated during apoptosis in the ageing rat prostate. Histochem J 32:571–580. https://doi.org/10.1023/a:1004110529753
doi: 10.1023/a:1004110529753
pubmed: 11127979
Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE (2008) Epidemiology of prostatitis. Int J Antimicrob Agents 31:85–90. https://doi.org/10.1016/j.ijantimicag.2007.08.028
doi: 10.1016/j.ijantimicag.2007.08.028
Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011–1015. https://doi.org/10.1038/35039519
doi: 10.1038/35039519
pubmed: 11069181
Zhang H, Liu L, Lu G, Chen Z, Fang Q, Yang Z, Li L, Li W, Song B, Zhou Z (2011) Chemical irritation of the prostate sensitizes P(2)X(3) receptor-mediated responses in rat dorsal root ganglion neurons. Neurourol Urodyn 30:612–618. https://doi.org/10.1002/nau.21060
doi: 10.1002/nau.21060
pubmed: 21254200
Schwartz ES, Xie A, La JH, Gebhart GF (2015) Nociceptive and inflammatory mediator upregulation in a mouse model of chronic prostatitis. Pain 156:1537–1544. https://doi.org/10.1097/j.pain.0000000000000201
doi: 10.1097/j.pain.0000000000000201
pubmed: 25915147
pmcid: 5260933
Zhang H, Liu L, Yang Z, Pan J, Chen Z, Fang Q, Li W, Li L, Lu G, Zhou Z (2013) P2X7 receptor mediates activation of microglial cells in prostate of chemically irritated rats. Int Braz J Urol 39:276–285. https://doi.org/10.1590/S1677-5538.IBJU.2013.02.17
doi: 10.1590/S1677-5538.IBJU.2013.02.17
pubmed: 23683674
Cheng Y, Mansfield KJ, Allen W, Chess-Williams R, Burcher E, Moore KH (2014) ATP during early bladder stretch is important for urgency in detrusor overactivity patients. Biomed Res Int 2014:204604. https://doi.org/10.1155/2014/204604
Abbasian B, Shair A, O'Gorman DB, Pena-Diaz AM, Brennan L, Engelbrecht K, Koenig DW, Reid G, Burton JP (2019) Potential role of extracellular ATP released by bacteria in bladder infection and contractility. mSphere 4:e00439–e00419. https://doi.org/10.1128/mSphere.00439-19
de Rivero Vaccari JP, Bastien D, Yurcisin G, Pineau I, Dietrich WD, De Koninck Y, Keane RW, Lacroix S (2012) P2X4 receptors influence inflammasome activation after spinal cord injury. J Neurosci: Off J Soc Neurosci 32:3058–3066. https://doi.org/10.1523/jneurosci.4930-11.2012
doi: 10.1523/jneurosci.4930-11.2012
Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, Pacher P, Haskó G (2018) Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight 3. https://doi.org/10.1172/jci.insight.99431
Wei Q, Costanzi S, Liu QZ, Gao ZG, Jacobson KA (2011) Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem Pharmacol 82:418–425. https://doi.org/10.1016/j.bcp.2011.05.013
doi: 10.1016/j.bcp.2011.05.013
pubmed: 21632028
pmcid: 3140712
Li WH, Qiu Y, Zhang HQ, Liu Y, You JF, Tian XX, Fang WG (2013) P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer 109:1666–1675. https://doi.org/10.1038/bjc.2013.484
doi: 10.1038/bjc.2013.484
pubmed: 23969730
pmcid: 3776994
Lertsuwan K et al (2017) Purinergic receptor expression and cellular responses to purinergic agonists in human prostate cancer cells. Anticancer Res 37:529–537. https://doi.org/10.21873/anticanres.11345
doi: 10.21873/anticanres.11345
pubmed: 28179298
Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS (2022) P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol 256(2):149–63 https://doi.org/10.1002/path.5815
Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G (2008) Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int 101:352–359. https://doi.org/10.1111/j.1464-410X.2007.07293.x
doi: 10.1111/j.1464-410X.2007.07293.x
pubmed: 18005209
Nandigama R, Padmasekar M, Wartenberg M, Sauer H (2006) Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells. J Biol Chem 281:5686–5693. https://doi.org/10.1074/jbc.M510452200
doi: 10.1074/jbc.M510452200
pubmed: 16321972
Chen L, He H-y, Li H-m, Zheng J, Heng W-j, You J-f, Fang W-g (2004) ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215:239–247. https://doi.org/10.1016/j.canlet.2004.05.023
doi: 10.1016/j.canlet.2004.05.023
pubmed: 15488643
Zhang Y, Gong L-h, Zhang H-q, Du Q, You J-f, Tian X-x, Fang W-g (2010) Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. Cancer Lett 293:189–197. https://doi.org/10.1016/j.canlet.2010.01.010
doi: 10.1016/j.canlet.2010.01.010
pubmed: 20202742
Slater M, Danieletto S, Barden JA (2005) Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol 36:159–165. https://doi.org/10.1007/s10735-004-6166-7
doi: 10.1007/s10735-004-6166-7
pubmed: 15900405
Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S, Di Virgilio F, McNulty S, Lara R (2019) ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene 38:194–208. https://doi.org/10.1038/s41388-018-0426-6
doi: 10.1038/s41388-018-0426-6
pubmed: 30087439
Ghalali A, Wiklund F, Zheng H, Stenius U, Högberg J (2014) Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis 35:1547–1555. https://doi.org/10.1093/carcin/bgu019
doi: 10.1093/carcin/bgu019
pubmed: 24451147
Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G (2015) Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget 6:28743–28754. https://doi.org/10.18632/oncotarget.4926
He J, Zhou Y, Arredondo Carrera HM, Sprules A, Neagu R, Zarkesh SA, Eaton C, Luo J, Gartland A, Wang N (2020) Inhibiting the P2X4 receptor suppresses prostate cancer growth in vitro and in vivo, suggesting a potential clinical target. Cells 9(11). https://doi.org/10.3390/cells9112511
Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, Eastham JA, Marchionni L, Joshu C, Gopalan A, Lotan TL (2020) PTEN loss with ERG negative status is associated with lethal disease after radical prostatectomy. J Urol 203:344–350. https://doi.org/10.1097/ju.0000000000000533
doi: 10.1097/ju.0000000000000533
pubmed: 31502941
Ghalali A, Ye Z-W, Högberg J, Stenius U (2020) PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells. Biomed Pharmacother 127:110112. https://doi.org/10.1016/j.biopha.2020.110112
doi: 10.1016/j.biopha.2020.110112
pubmed: 32294598
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL (2016) A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst 108(2). https://doi.org/10.1093/jnci/djv346
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (New York, N.Y.) 310:644–648. https://doi.org/10.1126/science.1117679
Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y, Duterque-Coquillaud M (2014) Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 33:2204–2214. https://doi.org/10.1038/onc.2013.176
Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583. https://doi.org/10.1053/hp.2000.6698
doi: 10.1053/hp.2000.6698
pubmed: 10836297
Falk S, Uldall M, Heegaard A-M (2012) The role of purinergic receptors in cancer-induced bone pain. J Osteoporos 758181–758181:2012. https://doi.org/10.1155/2012/758181
doi: 10.1155/2012/758181
Yan Y, Liang Y, Ding T, Chu H (2019) PI3K/Akt signaling pathway may be involved in MCP-1-induced P2X4R expression in cultured microglia and cancer-induced bone pain rats. Neurosci Lett 701:100–105. https://doi.org/10.1016/j.neulet.2019.02.024
doi: 10.1016/j.neulet.2019.02.024
pubmed: 30776493
Jin X-H, Wang L-N, Zuo J-L, Yang J-P, Liu S-L (2014) P2X4 receptor in the dorsal horn partially contributes to brain-derived neurotrophic factor oversecretion and toll-like receptor-4 receptor activation associated with bone cancer pain. J Neurosci Res 92:1690–1702. https://doi.org/10.1002/jnr.23443
doi: 10.1002/jnr.23443
pubmed: 24984884
Calvert RC, Khan MA, Thompson CS, Mikhailidis DP, Burnstock G (2008) A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. BJU Int 101:1043–1047. https://doi.org/10.1111/j.1464-410X.2007.07385.x
doi: 10.1111/j.1464-410X.2007.07385.x
pubmed: 18190636
Gur S, Hellstrom WJ (2009) Activation of P2Y1 and P2Y2 nucleotide receptors by adenosine 5’-triphosphate analogues augmented nerve-mediated relaxation of human corpus cavernosum. Can Urol Assoc J = J l’Assoc Urol Can 3:314–318. https://doi.org/10.5489/cuaj.1127
doi: 10.5489/cuaj.1127
Lau DH, Metcalfe MJ, Mumtaz FH, Mikhailidis DP, Thompson CS (2009) Purinergic modulation of human corpus cavernosum relaxation. Int J Androl 32:149–155. https://doi.org/10.1111/j.1365-2605.2007.00828.x
doi: 10.1111/j.1365-2605.2007.00828.x
pubmed: 17971163
Odom MR, Pak ES, Brown DA, Hannan JL (2017) Enhanced electrical field stimulated nitrergic and purinergic vasoreactivity in distal vs proximal internal pudendal arteries. J Sex Med 14:1285–1296. https://doi.org/10.1016/j.jsxm.2017.09.013
doi: 10.1016/j.jsxm.2017.09.013
pubmed: 29110801
pmcid: 5828175
Gur S, Kadowitz PJ, Abdel-Mageed AB, Kendirci M, Sikka SC, Burnstock G, Hellstrom WJG (2009) Management of erectile function by penile purinergic p2 receptors in the diabetic rat. J Urol 181:2375–2382. https://doi.org/10.1016/j.juro.2009.01.002
Gur S, Sikka SC, Knight GE, Burnstock G, Hellstrom WJG (2010) Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. Asian J Androl 12:415–421. https://doi.org/10.1038/aja.2009.70
doi: 10.1038/aja.2009.70
pubmed: 20305675
pmcid: 3739254
Shalev M, Staerman F, Allain H, Lobel B, Saiag B (1999) Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum. J Urol 161:955–959
doi: 10.1016/S0022-5347(01)61828-7
Kilicarslan H, Yildirim S, Bagcivan I, Ayan S, Sarac B, Sarioglu Y (2002) Effect of chronic renal failure on the purinergic responses of corpus cavernosal smooth muscle in rabbits. BJU Int 90:596–600. https://doi.org/10.1046/j.1464-410x.2002.02979.x
doi: 10.1046/j.1464-410x.2002.02979.x
pubmed: 12230624
Yildirim MK, Bagcivan I, Sarac B, Kilicarslan H, Yildirim S, Kaya T (2008) Effect of hypothyroidism on the purinergic responses of corpus cavernosal smooth muscle in rabbits. Int Urol Nephrol 40:691–699. https://doi.org/10.1007/s11255-008-9332-0
doi: 10.1007/s11255-008-9332-0
pubmed: 18327655
Faria M, Magalhaes-Cardoso T, Lafuente-de-Carvalho JM, Correia-de Sa P (2008) Decreased ecto-NTPDase1/CD39 activity leads to desensitization of P2 purinoceptors regulating tonus of corpora cavernosa in impotent men with endothelial dysfunction. Nucleosides, Nucleotides and Nucleic Acids 27:761–768. https://doi.org/10.1080/15257770802145744
doi: 10.1080/15257770802145744
pubmed: 18600538
Liu P, Jiang J, Xia J, Jiang R (2018) Effect of low androgen status on the expression of P2Y receptors in the corpus cavernosum of rats. Urology 116(229):e221-229.e226. https://doi.org/10.1016/j.urology.2018.03.018
doi: 10.1016/j.urology.2018.03.018
Li CL, Yang XL, Wang JJ, Du GH, Yang WM, Zhang HP (2015) Effects of intracavernous injection of P2X3 and NK1 receptor antagonists on erectile dysfunction induced by spinal cord transection in rats. Andrologia 47:25–29. https://doi.org/10.1111/and.12217
doi: 10.1111/and.12217
pubmed: 24387161
Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, Evans RJ (2000) Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403:86–89. https://doi.org/10.1038/47495
doi: 10.1038/47495
pubmed: 10638758
White CW, Choong YT, Short JL, Exintaris B, Malone DT, Allen AM, Evans RJ, Ventura S (2013) Male contraception via simultaneous knockout of alpha1A-adrenoceptors and P2X1-purinoceptors in mice. Proc Natl Acad Sci USA 110:20825–20830. https://doi.org/10.1073/pnas.1318624110
doi: 10.1073/pnas.1318624110
pubmed: 24297884
pmcid: 3870707
Walenta L, Fleck D, Frohlich T, von Eysmondt H, Arnold GJ, Spehr J, Schwarzer JU, Kohn FM, Spehr M, Mayerhofer A (2018) ATP-mediated events in peritubular cells contribute to sterile testicular inflammation. Sci Rep 8:1431. https://doi.org/10.1038/s41598-018-19624-3
Fleck D, Kenzler L, Mundt N, Strauch M, Uesaka N, Moosmann R, Bruentgens F, Missel A, Mayerhofer A, Merhof D, Spehr J, Spehr M (2021) ATP activation of peritubular cells drives testicular sperm transport. Elife 10:e62885. https://doi.org/10.7554/eLife.62885
Giuliani AL, Sarti AC and Di Virgilio F (2021) Ectonucleotidases in acute and chronic inflammation. Front Pharmacol 11:619458. https://doi.org/10.3389/fphar.2020.619458
Zylka MJ (2011) Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 17:188–196. https://doi.org/10.1016/j.molmed.2010.12.006
doi: 10.1016/j.molmed.2010.12.006
pubmed: 21236731
pmcid: 3078941
Haas CB, Lovászi M, Braganhol E, Pacher P, Haskó G (2021) (2021) Ectonucleotidases in inflammation immunity and cancer. J Immunol Baltimore (Baltimore, Md. : 1950) 206:1983–1990
Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32:1743–1751. https://doi.org/10.1038/onc.2012.269
doi: 10.1038/onc.2012.269
pubmed: 22751118
Dwyer KM, Kishore BK, Robson SC (2020) Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol 16:509–524. https://doi.org/10.1038/s41581-020-0304-7
doi: 10.1038/s41581-020-0304-7
pubmed: 32641760
Yu W, Robson SC, Hill WG (2011) Expression and distribution of ectonucleotidases in mouse urinary bladder. PLoS ONE 6:e18704. https://doi.org/10.1371/journal.pone.0018704
doi: 10.1371/journal.pone.0018704
pubmed: 21533188
pmcid: 3077397
Yu W, Sun X, Robson SC, Hill WG (2014) ADP-induced bladder contractility is mediated by P2Y12 receptor and temporally regulated by ectonucleotidases and adenosine signaling. FASEB J 28:5288–5298. https://doi.org/10.1096/fj.14-255885
doi: 10.1096/fj.14-255885
pubmed: 25208846
pmcid: 4232283
Kauffenstein G, Pelletier J, Lavoie EG, Kukulski F, Martín-Satué M, Dufresne SS, Frenette J, Ribas Fürstenau C, Sereda MJ, Toutain B, Henrion D, Sullivan R, Vial C, Sévigny J (2014) Nucleoside triphosphate diphosphohydrolase-1 ectonucleotidase is required for normal vas deferens contraction and male fertility through maintaining P2X1 receptor function*. J Biol Chem 289:28629–28639. https://doi.org/10.1074/jbc.M114.604082
doi: 10.1074/jbc.M114.604082
pubmed: 25160621
pmcid: 4192512
Ferreira JM, Matheus LHG, Almeida RVSd, Melo PAdS, Leite KRM, Murta CB, Claro JFdA, Camacho CP, Pontes-Júnior J, Dellê H (2021) High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer. Oncotarget 12(16):1580–1586. https://doi.org/10.18632/oncotarget.28029
Gardani CFF, Cappellari AR, de Souza JB, da Silva BT, Engroff P, Moritz CEJ, Scholl JN, Battastini AMO, Figueiró F, Morrone FB (2019) Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients. Purinergic Signalling 15:95–105. https://doi.org/10.1007/s11302-018-9642-3
doi: 10.1007/s11302-018-9642-3
pubmed: 30644036
pmcid: 6438999
Battisti V, Maders LDK, Bagatini MD, Battisti IE, Bellé LP, Santos KF, Maldonado PA, Thomé GR, Schetinger MRC, Morsch VM (2013) Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: influence of Gleason score, treatment and bone metastasis. Biomed Pharmacother 67:203–208. https://doi.org/10.1016/j.biopha.2012.12.004
doi: 10.1016/j.biopha.2012.12.004
pubmed: 23433854
Plavix/Clopidogrel bisulfate Drug Approval Package (1997) U. S. Food & Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/nda/97/020839_plavix_toc.cfm . Accessed 24 Nov 2020
The safety and efficacy of gefapixant (AF-219/MK-7264) in female subjects with interstitial cystitis bladder pain syndrome. ClinicalTrials.gov identifier: NCT01569438. Updated 17 August 2020. https://ClinicalTrials.gov/show/NCT01569438
A four-week multicenter study evaluating the safety and efficacy of gefapixant (AF-219/MK-7264) in subjects with osteoarthritis of the knee. ClinicalTrials.gov identifier: NCT01554579. Updated 27 June 2019. https://ClinicalTrials.gov/show/NCT01554579
Efficacy and safety of gefapixant (MK-7264) in women with chronic cough and stress Urinary Incontinence (MK-7264-042). ClinicalTrials.gov identifier: NCT04193176. Updated 26 April 2022. https://ClinicalTrials.gov/show/NCT04193176
A Randomised, Placebo-controlled, Double-blind Trial of the Antidepressant Efficacy of a Novel CNS-penetrant P2X7 Receptor Antagonist, JNJ-54175446, in People With Major Depressive Disorder, an Incomplete Response to Monoaminergic Antidepressant Drugs, and a Biomarker Profile Predictive of Active P2X7 Signalling. ClinicalTrials.gov identifier: NCT04116606. Updated 11 May 2022. https://ClinicalTrials.gov/show/NCT04116606
A PHASE 2A, Randomized, double-blind, placebo-controlled, parallel-group study of CE-224,535, an antagonist of the P2X7 receptor, in the treatment of the signs and symptoms of rheumatoid arthritis in subjects who are inadequately controlled on Methotrexate. ClinicalTrials.gov identifier: NCT00628095. Updated April 2022. https://ClinicalTrials.gov/show/NCT00628095
A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine. ClinicalTrials.gov identifier: NCT00520572. Updated February 2013. https://ClinicalTrials.gov/show/NCT00520572
A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to Make a Preliminary Assessment of the Effect of Food. ClinicalTrials.gov identifier: NCT00849134. Updated 7 July 2017. https://ClinicalTrials.gov/show/NCT00849134
Ali Z, Laurijssens B, Ostenfeld T, McHugh S, Stylianou A, Scott-Stevens P, Hosking L, Dewit O, Richardson JC, Chen C (2013) Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol 75:197–207. https://doi.org/10.1111/j.1365-2125.2012.04320.x
doi: 10.1111/j.1365-2125.2012.04320.x
pubmed: 22568863
A Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Subjects. ClinicalTrials.gov identifier: NCT03151486. Updated 19 April 2018 https://ClinicalTrials.gov/show/NCT03151486
An Open-Label Phase 1 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment When Applied Twice Daily for 28 Days in Male and Female Patients With Basal Cell Carcinoma. ClinicalTrials.gov identifier: NCT002587819. Updated 4 April 2016. https://ClinicalTrials.gov/show/NCT02587819
An Open-label PET Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739. ClinicalTrials.gov identifier: NCT03437590. Updated 23 January 2019 https://ClinicalTrials.gov/show/NCT03437590 )
Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, King J (2017) A phase I clinical trial demonstrates that nfP2X(7) -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol 177:117–124. https://doi.org/10.1111/bjd.15364
doi: 10.1111/bjd.15364
pubmed: 28150889
A Multi-Center, Parallel Group, Double-Masked, Randomized, Placebo-Controlled Study of Multiple Ocular Instillations of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease. ClinicalTrials.gov identifier: NCT00403975. Updated 22 February 2016. https://ClinicalTrials.gov/show/NCT00403975
A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% and Placebo in Subjects With Dry Eye Disease. ClinicalTrials.gov identifier: NCT02116010. Updated 9 January 2015. https://ClinicalTrials.gov/show/NCT00600288 )
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease. ClinicalTrials.gov identifier: NCT00404131. Updated 29 November 2016 https://ClinicalTrials.gov/show/NCT00404131 )
SDouble-Masked, Randomized, Placebo-Controlled Study of Efficacy Parameter Following Administration of INS365 Ophthalmic Solution or Placebo in a Controlled Adverse Environment (CAE) Chamber in Subjects With Non-Sjogren's Associated Dry Eye. ClinicalTrials.gov identifier: NCT00037661. Updated 2 October 2015. ( https://ClinicalTrials.gov/show/NCT00037661 )
Mun Y, Kwon J-W, Oh JY (2018) Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease. BMC Ophthalmol 18:237–237. https://doi.org/10.1186/s12886-018-0910-3
doi: 10.1186/s12886-018-0910-3
pubmed: 30185156
pmcid: 6126033
Park DH, Chung JK, Seo DR, Lee SJ (2016) Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial. Am J Ophthalmol 163:122-131.e122. https://doi.org/10.1016/j.ajo.2015.12.002
doi: 10.1016/j.ajo.2015.12.002
pubmed: 26685791
A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted. ClinicalTrials.gov identifier: NCT00625612. Updated 1 November 2015 https://ClinicalTrials.gov/show/NCT00625612 )
Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB (2012) Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 11:539–549. https://doi.org/10.1016/j.jcf.2012.05.003
doi: 10.1016/j.jcf.2012.05.003
pubmed: 22682898
de Baaij JH, Kompatscher A, Viering DH, Bos C, Bindels RJ, Hoenderop JG (2016) P2X6 knockout mice exhibit normal electrolyte homeostasis. PLoS ONE 11:e0156803. https://doi.org/10.1371/journal.pone.0156803
Vial C, Evans RJ (2001) Smooth muscle does not have a common P2X receptor phenotype: expression, ontogeny and function of P2x1 receptors in mouse ileum, bladder and reproductive systems. Auton Neurosci : Basic Clin 92:56–64. https://doi.org/10.1016/s1566-0702(01)00319-8
doi: 10.1016/s1566-0702(01)00319-8
Banks FC, Calvert RC, Burnstock G (2010) Changing P2X receptor localization on maturing sperm in the epididymides of mice, hamsters, rats, and humans: a preliminary study. Fertil Steril 93:1415–1420. https://doi.org/10.1016/j.fertnstert.2009.02.061
doi: 10.1016/j.fertnstert.2009.02.061
pubmed: 19338992
Yu W, Hill WG, Robson SC, Zeidel ML (2018) Role of P2X4 receptor in mouse voiding function. Sci Rep 8:1838. https://doi.org/10.1038/s41598-018-20216-4
doi: 10.1038/s41598-018-20216-4
pubmed: 29382907
pmcid: 5789870
Suadicani SO, Urban-Maldonado M, Tar MT, Melman A, Spray DC (2009) Effects of ageing and streptozotocin-induced diabetes on connexin43 and P2 purinoceptor expression in the rat corpora cavernosa and urinary bladder. BJU Int 103:1686–1693. https://doi.org/10.1111/j.1464-410X.2008.08337.x
doi: 10.1111/j.1464-410X.2008.08337.x
pubmed: 19154470
pmcid: 3422638
Wang ECY, Lee J-M, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, Cockayne DA, Birder LA, Apodaca G (2005) ATP and purinergic receptor–dependent membrane traffic in bladder umbrella cells. J Clin Investig 115:2412–2422. https://doi.org/10.1172/JCI24086
doi: 10.1172/JCI24086
pubmed: 16110327
pmcid: 1187935
Guan NN, Sharma N, Hallén-Grufman K, Jager EWH, Svennersten K (2018) The role of ATP signalling in response to mechanical stimulation studied in T24 cells using new microphysiological tools. J Cell Mol Med 22:2319–2328. https://doi.org/10.1111/jcmm.13520
doi: 10.1111/jcmm.13520
pubmed: 29392898
pmcid: 5867107
Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G (2008) Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int 101:106–112. https://doi.org/10.1111/j.1464-410X.2007.07286.x
doi: 10.1111/j.1464-410X.2007.07286.x
pubmed: 17941929